US3885035A - Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines - Google Patents

Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines Download PDF

Info

Publication number
US3885035A
US3885035A US333556A US33355673A US3885035A US 3885035 A US3885035 A US 3885035A US 333556 A US333556 A US 333556A US 33355673 A US33355673 A US 33355673A US 3885035 A US3885035 A US 3885035A
Authority
US
United States
Prior art keywords
bis
quinazolinyl
compound
piperazine
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US333556A
Inventor
William R Simpson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Sandoz Wander Inc
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to US333556A priority Critical patent/US3885035A/en
Application granted granted Critical
Publication of US3885035A publication Critical patent/US3885035A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • This invention relates to the pharmaceutical activity of bis(4-quinazo-linyl)piperazine derivatives. More particularly, this invention concerns the use of 1,4- bis(4-quinazolinyl) piperazines in the treatment of arrhythmia in mammals. The invention also relates to pharmaceutical compositions containing the above compounds as an active ingredient thereof.
  • the active agents with which this invention is concerned may be represented by the following structural formula:
  • R, and R each independently represent hydrogen or lower alkoxy i.e., alkoxy having 1 to 4 carbons atoms, e.g., methoxy, ethoxy, isopropoxy and the like, or a pharmaceutically acceptable acid addition salt thereof.
  • the preferred compound of formula (I) is the compound in which R, and R are both methoxy, namely 1,4-bis (6,7-dimethoxy-4-quinazolinyl)piperazine.
  • the compounds of formula (1) above are known and may be prepared according to methods disclosed in the literature from known materials, for example as described in Example XIV of U.S. Pat. No. 3,594,480.
  • the present invention contemplates only the novel use of such compounds in pharmaceutical applications, in particular in the treatment of arrhythmia.
  • the compounds of formula (I) are useful in animals as anti-arrhythmic agents as indicated by polygraph recordings on anesthetized dogs given micrograms per kilogram of oubain every 10 minutes until the appearance of constantly-occurring ventricular ectopic beats following which 0.1 to 10 milligrams per kilogram of the test compound is administered intravenously every two minutes until the arrhythmia reverts to sinus rhythm.
  • the dog is anesthetized with 30 mg/kg i.v., of sodium pentobarbitol and the polygraph recordings are made with a lead II electrocardiogram using pressure transducers connected to the cannulated fermoral artery.
  • the compounds may be administered orally or parenterally as such or admixed with conventional pharmaceutical carriers. They may be administered in such forms as tablets, dispersible powders, granules, capsules, syrups and elixirs and parenterally as solutions, suspensions, dispersions, emulsions and the like, e.g. a sterile injectable aqueous solution.
  • the compositions may contain one or more conventional adjuvants, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide an elegant and palatable preparation.
  • Tablets may contain the active ingredient in admixture with conventional pharmaceutically acceptable excipients, e.g., inert diluents, such as calcium carbonate, sodium carbonate, lactose and talc, granulating and disintegrating agents, e.g., starch and alginic acid, binding agents, e.g., starch, gelatin and acacia, and lubricating agents, e.g., magnesium stearate, stearic acid and talc.
  • excipients e.g., inert diluents, such as calcium carbonate, sodium carbonate, lactose and talc
  • granulating and disintegrating agents e.g., starch and alginic acid
  • binding agents e.g., starch, gelatin and acacia
  • lubricating agents e.g., magnesium stearate, stearic acid and talc.
  • the tablets may be uncoated or coated
  • oral liquids e.g., suspensions may contain the active ingredient in admixture with any of the conventional excipients utilized for the preparation of such compositions, e.g., suspending agents (methylcellulose, tragacanth and sodium alginate) wetting agents (lecithin, polyoxyethylene stearate and polyoxy-ethylene sorbitan mono-oleate) and preservatives (ethyl-o-hydroxybenzoate).
  • suspending agents methylcellulose, tragacanth and sodium alginate
  • wetting agents lecithin, polyoxyethylene stearate and polyoxy-ethylene sorbitan mono-oleate
  • preservatives ethyl-o-hydroxybenzoate
  • Capsules may contain the active ingredient alone or admixed with'an inert solid diluent, e.g., calcium carbonate, calcium phosphate and kaolin.
  • the injectable compositions are formulated 'as known in the art. These pharmaceutical preparations
  • the compounds of formula (I) may be similarly administered in the form of their non-toxic pharmaceutically acceptable acid addition salts.
  • the anti-arrhythmic effective dosage of the compounds of formula (I) employed in the alleviation of arrhythmia may vary depending on the. particular compound employed and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of formula (I) are administered at a daily dosage of from about 3 milligrams to about 300 milligrams per kilogram of animal body weight, preferably given in divided doses two to four times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 200milligrams to about 3000 milligrams. Dosage forms suitable for internal use comprise'from about 50 to about 1500 milligrams of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier or diluent.
  • compositions from the standpoint of preparation and ease of administration are solid compositions, particularly hardfilled capsules and tablets containing from about to 250 milligrams of the active ingredient.
  • Tablets and capsules containing the ingredients indicated below may be prepared by conventional tech- 3 4 niques and are useful in treating arrhythmia at a dose What is claimed is: of one tablet or capsule 2 to 4 times a day. l.
  • a method for treating arrhythmia which comprises administering to a mammal in need of said treatment an anti-arrhythmic effective amount of a comlngred'em weigh (mg) 5 pound of the formula:
  • tablets and capsules may be pre- X pared using l,4-bis(4-quinazolinyl)piperazine or 1,4- R bis(7methoxy-4-quinazolinyl)-piperazine as the active 2 ingredient in place of the l,4-bis(6,7-dimethoxy-4- quinazolinyl)piperazine above.
  • compositions are for- 2.
  • the in'ectable sus en- 200 milli rams to about 3000 milligrams.
  • the injectable suspension said compound to the extent of from about milliis suitable for administration once or twice a day 30 grams to about 1500 milligrams per unit dosage.
  • pound is l,4-bis(6,7-dimethoxy-4-quinazolinyl)pipera- Ingredients Weight (mg) injectable suspension liquid suspension l,4-bis( 6,7-dimethoxy-4- quinazolinyl)piperazine 200 200 sodium carboxy methyl cellulose U.S.P. 1.25 12.5 methyl cellulose 0.4 polyvinylpyrrolidone 5 lecithin 3 benzyl alcohol 0.01 magnesium aluminum silicate 47.5 flavor q.s. color q.s. mathyl paraben. U.S.P. 4.5 propyl paraben.
  • U.S.P. l.0 polysorbate 80 e.g. Tween 80
  • USP 5 sorbitol solution e.g. Tween 80
  • 70% e.g., USP 2,500 buffer agent to adjust pH for desired stability q.s. q.s. water for injection. q.s. to 5 ml.
  • injectable suspensions and liquid zine. suspension may be prepared using l,4-bis(4- 5.
  • a method according to claim 1 in which the comdient in place of the 1,4-bis (6,7-dimethoxy-4- pound is l,4-bis(7-methoxy-4-quinazolinyl)piperazine. quinazolinyl)piperazine above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Certain bis(4-quinazolinyl) piperazines, e.g., 1,4-bis(6,7dimethoxy-4-quinazolinyl)piperazine, are useful as antiarrhythmic agents.

Description

United States Patent Simpson 1 May 20, 1975 METHOD FOR TREATING ARRHYTHMIA BY USING 1,4-BlS(4 QUINAZOLINYL) PIPERAZINES William R. Simpson, Mendham, NJ.
Sandoz-Wander, lnc., E. Hanover, NJ.
Filed: Feb. 20, 1973 Appl. No.: 333,556
Related US. Application Data Continuation-in-part of Ser. No. 241,408, April 5, 1972, abandoned.
Inventor:
Assignee:
US. Cl. 424/251 Int. Cl A61k 27/00 Field of Search 424/251 [56] References Cited UNITED STATES PATENTS 3,594,480 7/1971 Cronin et al 424/250 [57] ABSTRACT Certain bis(4-quinazolinyl) piperazines, e.g., 1,4- bis(6,7-dimethoxy-4-quinazolinyl)piperazine, are useful as anti-arrhythmic agents.
6 Claims, No Drawings METHOD FOR TREATING ARRHYTHMIA BY USING 1,4-BIS(4 QUINAZOLINYL) PIPERAZINES This application is a continuation-in-part of copending U.S. Pat. Application, Ser. No. 241,408 filed Apr. 5, 1972 now abandoned.
This invention relates to the pharmaceutical activity of bis(4-quinazo-linyl)piperazine derivatives. More particularly, this invention concerns the use of 1,4- bis(4-quinazolinyl) piperazines in the treatment of arrhythmia in mammals. The invention also relates to pharmaceutical compositions containing the above compounds as an active ingredient thereof.
The active agents with which this invention is concerned may be represented by the following structural formula:
ll 2 (I) n E N where R, and R each independently represent hydrogen or lower alkoxy i.e., alkoxy having 1 to 4 carbons atoms, e.g., methoxy, ethoxy, isopropoxy and the like, or a pharmaceutically acceptable acid addition salt thereof.
The preferred compound of formula (I) is the compound in which R, and R are both methoxy, namely 1,4-bis (6,7-dimethoxy-4-quinazolinyl)piperazine.
The compounds of formula (1) above are known and may be prepared according to methods disclosed in the literature from known materials, for example as described in Example XIV of U.S. Pat. No. 3,594,480. The present invention contemplates only the novel use of such compounds in pharmaceutical applications, in particular in the treatment of arrhythmia.
As indicated above, the compounds of formula (I) are useful in animals as anti-arrhythmic agents as indicated by polygraph recordings on anesthetized dogs given micrograms per kilogram of oubain every 10 minutes until the appearance of constantly-occurring ventricular ectopic beats following which 0.1 to 10 milligrams per kilogram of the test compound is administered intravenously every two minutes until the arrhythmia reverts to sinus rhythm. The dog is anesthetized with 30 mg/kg i.v., of sodium pentobarbitol and the polygraph recordings are made with a lead II electrocardiogram using pressure transducers connected to the cannulated fermoral artery.
For such usage, the compounds may be administered orally or parenterally as such or admixed with conventional pharmaceutical carriers. They may be administered in such forms as tablets, dispersible powders, granules, capsules, syrups and elixirs and parenterally as solutions, suspensions, dispersions, emulsions and the like, e.g. a sterile injectable aqueous solution. The compositions may contain one or more conventional adjuvants, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide an elegant and palatable preparation. Tablets may contain the active ingredient in admixture with conventional pharmaceutically acceptable excipients, e.g., inert diluents, such as calcium carbonate, sodium carbonate, lactose and talc, granulating and disintegrating agents, e.g., starch and alginic acid, binding agents, e.g., starch, gelatin and acacia, and lubricating agents, e.g., magnesium stearate, stearic acid and talc. The tablets may be uncoated or coated by known techniques to delay disintegration and absorption in the gastro intestinal tract and thereby provide a sustained action over a longer period. Similarly, oral liquids, e.g., suspensions may contain the active ingredient in admixture with any of the conventional excipients utilized for the preparation of such compositions, e.g., suspending agents (methylcellulose, tragacanth and sodium alginate) wetting agents (lecithin, polyoxyethylene stearate and polyoxy-ethylene sorbitan mono-oleate) and preservatives (ethyl-o-hydroxybenzoate). Capsules may contain the active ingredient alone or admixed with'an inert solid diluent, e.g., calcium carbonate, calcium phosphate and kaolin. The injectable compositions are formulated 'as known in the art. These pharmaceutical preparations may contain up to about percent of the active ingredient in combination with the carrier or adjuvant.
Furthermore, the compounds of formula (I) may be similarly administered in the form of their non-toxic pharmaceutically acceptable acid addition salts. Such malate, tartrate, methanesulfonate, cyclohexylsulfamate and the like.
The anti-arrhythmic effective dosage of the compounds of formula (I) employed in the alleviation of arrhythmia may vary depending on the. particular compound employed and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of formula (I) are administered at a daily dosage of from about 3 milligrams to about 300 milligrams per kilogram of animal body weight, preferably given in divided doses two to four times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 200milligrams to about 3000 milligrams. Dosage forms suitable for internal use comprise'from about 50 to about 1500 milligrams of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier or diluent.
The preferred pharmaceutical compositions from the standpoint of preparation and ease of administration are solid compositions, particularly hardfilled capsules and tablets containing from about to 250 milligrams of the active ingredient.
EXAMPLES 1 AND 2 Tablets and Capsules Suitable For Oral Administration Tablets and capsules containing the ingredients indicated below may be prepared by conventional tech- 3 4 niques and are useful in treating arrhythmia at a dose What is claimed is: of one tablet or capsule 2 to 4 times a day. l. A method for treating arrhythmia, which comprises administering to a mammal in need of said treatment an anti-arrhythmic effective amount of a comlngred'em weigh (mg) 5 pound of the formula:
tablet capsule l,4-bis( 6,7-dimethoxy-4-quinazol R linyl) piperazine 150 150 1 tragacanth l l lactose 297.5 150 corn starch 25 [0 N talcum l R 1 magnesium stearate 2.5 Total 500 mg. 300 mg. [N] In a similar manner, tablets and capsules may be pre- X pared using l,4-bis(4-quinazolinyl)piperazine or 1,4- R bis(7methoxy-4-quinazolinyl)-piperazine as the active 2 ingredient in place of the l,4-bis(6,7-dimethoxy-4- quinazolinyl)piperazine above. Rl
EXAMPLES 3 AND 4 h d where R and R each independently represent y ro- Stenle Suspenslon and Oral Llquld gen or lower alkoxy or a pharmaceutically acceptable uspenslon acid addition salt thereof.
The following pharmaceutical compositions are for- 2. A method according to claim 1 wherein the commulated with the indicated amount of the active agent pound is administered at a daily dosage of .from about usin conventional techni ues. The in'ectable sus en- 200 milli rams to about 3000 milligrams.
8 q .l P g sion and the oral li uid sus ension re resent formula- 3. A method according to claim 1 where in the comq p p a u tions useful as unit doses and ma be administered in ound is administered in a unit dosage form comprlsmg the treatment of arrhythmia. The injectable suspension said compound to the extent of from about milliis suitable for administration once or twice a day 30 grams to about 1500 milligrams per unit dosage.
whereas the oral liquid suspension is suitable adminis- 4. A method according to claim 1 in which the comtered 2 to 4 times per day for this purpose. pound is l,4-bis(6,7-dimethoxy-4-quinazolinyl)pipera- Ingredients Weight (mg) injectable suspension liquid suspension l,4-bis( 6,7-dimethoxy-4- quinazolinyl)piperazine 200 200 sodium carboxy methyl cellulose U.S.P. 1.25 12.5 methyl cellulose 0.4 polyvinylpyrrolidone 5 lecithin 3 benzyl alcohol 0.01 magnesium aluminum silicate 47.5 flavor q.s. color q.s. mathyl paraben. U.S.P. 4.5 propyl paraben. U.S.P. l.0 polysorbate 80 (e.g. Tween 80), USP 5 sorbitol solution, 70%, USP 2,500 buffer agent to adjust pH for desired stability q.s. q.s. water for injection. q.s. to 5 ml.
' q.s. to 1 ml.
In a similar manner, injectable suspensions and liquid zine. suspension may be prepared using l,4-bis(4- 5. A method according to claim 1 in which the comquinazolinyl)piperazine or l,4-bis(7- pound is l,4-bis(4-quinazolinyl)piperazine. methoxy-4-quinazolinyl)piperazine as the active ingre- 6. A method according to claim 1 in which the comdient in place of the 1,4-bis (6,7-dimethoxy-4- pound is l,4-bis(7-methoxy-4-quinazolinyl)piperazine. quinazolinyl)piperazine above.

Claims (6)

1. A METHOD FOR TREATING ARRHYTHMIA WHICH COMPRISES ADMINISTERING TO A MAMMAL IN NEED OF SAID TREATMENT AN ANTIARRTHYMIC EFFECTIVE AMOUNT OF A COMPOUND OF THE FORMULA
2. A method according to claim 1 wherein the compound is administered at a daily dosage of from about 200 milligrams to about 3000 milligrams.
3. A method according to claim 1 where in the compound is administered in a unit dosage form comprising said compound to the extent of from about 50 milligrams to about 1500 milligrams per unit dosage.
4. A method according to claim 1 in which the compound is 1,4-bis(6,7-dimethoxy-4-quinazolinyl)piperazine.
5. A method according to claim 1 in which the compound is 1,4-bis(4-quinazolinyl)piperazine.
6. A method according to claim 1 in which the compound is 1,4-bis(7-methoxy-4-quinazolinyl)piperazine.
US333556A 1972-04-05 1973-02-20 Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines Expired - Lifetime US3885035A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US333556A US3885035A (en) 1972-04-05 1973-02-20 Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24140872A 1972-04-05 1972-04-05
US333556A US3885035A (en) 1972-04-05 1973-02-20 Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines

Publications (1)

Publication Number Publication Date
US3885035A true US3885035A (en) 1975-05-20

Family

ID=26934278

Family Applications (1)

Application Number Title Priority Date Filing Date
US333556A Expired - Lifetime US3885035A (en) 1972-04-05 1973-02-20 Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines

Country Status (1)

Country Link
US (1) US3885035A (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051304A2 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
US20080051399A1 (en) * 2006-07-06 2008-02-28 Mitchell Ian S Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US20080058327A1 (en) * 2006-07-06 2008-03-06 Mitchell Ian S Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US20100292244A1 (en) * 2008-01-09 2010-11-18 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
US20110065716A1 (en) * 2008-01-09 2011-03-17 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US20110160221A1 (en) * 2007-07-05 2011-06-30 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9150549B2 (en) 2011-04-01 2015-10-06 Genentech, Inc. Combinations of AKT inhibitor compounds and erlotinib, and methods of use
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594480A (en) * 1966-10-31 1971-07-20 Pfizer Nitrogen heterocycles for therapeutic administration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594480A (en) * 1966-10-31 1971-07-20 Pfizer Nitrogen heterocycles for therapeutic administration

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680114B2 (en) 2003-11-21 2014-03-25 Array Biopharma, Inc. AKT protein kinase inhibitors
WO2005051304A3 (en) * 2003-11-21 2006-07-27 Array Biopharma Inc Akt protein kinase inhibitors
WO2005051304A2 (en) * 2003-11-21 2005-06-09 Array Biopharma Inc. Akt protein kinase inhibitors
KR101223914B1 (en) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Akt protein kinase inhibitors
US20100168123A1 (en) * 2003-11-21 2010-07-01 Mitchell Ian S Akt protein kinase inhibitors
CN102786482A (en) * 2003-11-21 2012-11-21 阿雷生物药品公司 Akt protein kinase inhibitors
US9303040B2 (en) 2006-07-06 2016-04-05 Array Biopharma Inc. Substituted piperazines as AKT inhibitors
US8853199B2 (en) 2006-07-06 2014-10-07 Array Biopharma, Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8003651B2 (en) 2006-07-06 2011-08-23 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US9359340B2 (en) 2006-07-06 2016-06-07 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US20080058327A1 (en) * 2006-07-06 2008-03-06 Mitchell Ian S Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8846681B2 (en) 2006-07-06 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20080051399A1 (en) * 2006-07-06 2008-02-28 Mitchell Ian S Hydroxylated and methoxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8618097B2 (en) 2007-07-05 2013-12-31 Array Biopharma, Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20110160221A1 (en) * 2007-07-05 2011-06-30 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8377937B2 (en) 2007-07-05 2013-02-19 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US20100292244A1 (en) * 2008-01-09 2010-11-18 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
US20110065716A1 (en) * 2008-01-09 2011-03-17 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8835434B2 (en) 2008-01-09 2014-09-16 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
US9150549B2 (en) 2011-04-01 2015-10-06 Genentech, Inc. Combinations of AKT inhibitor compounds and erlotinib, and methods of use
US9150548B2 (en) 2011-04-01 2015-10-06 Genentech, Inc. Combinations of AKT inhibitor compounds and vemurafenib, and methods of use
US9346789B2 (en) 2011-04-01 2016-05-24 Genentech, Inc. Combinations of AKT inhibitor compounds and abiraterone, and methods of use
US9610289B2 (en) 2011-04-01 2017-04-04 Genentech, Inc. Combinations of AKT inhibitor compounds and erlotinib, and methods of use
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
US9717730B2 (en) 2011-04-01 2017-08-01 Genentech, Inc. Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
US10092567B2 (en) 2011-04-01 2018-10-09 Genentech, Inc. Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use

Similar Documents

Publication Publication Date Title
US4929632A (en) Medicaments
US3885035A (en) Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
US3949089A (en) Substituted guanidine compounds as antifibrillatory agents
US5922749A (en) Medicaments for treating nausea and vomiting
US6372763B1 (en) Treatment and prevention of cardiac disorders using selective serotonin re-uptake inhibitors (SSRI)
US3592935A (en) Substituted benzylidene hydrazines as anti-inflammatory agents
US3857944A (en) 1-piperazinoisoquinolines as inotropic agents
US4212876A (en) Substituted or unsubstituted 2-phenylbenzimidazoles as anti-obesity agents
US4315003A (en) Compositions containing azo compounds and use thereof for therapeutic treatment
US4031220A (en) Method for the treatment of malaria
US4522820A (en) Trans-dihydrolisuride antipsychotic
US3658964A (en) 2-phenylacetylbenzoic acid in the treatment of inflammation
US4148906A (en) Growth hormone inhibitors
US4225605A (en) Ergolene or ergoline compounds for treating congestive heart failure
EP0342211B1 (en) Treatment of arteriosclerosis by administration of l-tryptophan or l-5-hydroxytryptophan
US3622671A (en) Substituted 3-hydrazino pyridazines as hypotensives
US3963834A (en) Pharmaceutical compositions for the treatment of hydropic conditions
US3867532A (en) Diazabicyclodecanes as anti-ulcer agents
US4874762A (en) 2-amino-4-nicotinoylamino-6-aryl-s-triazines as nootropic agents
US3968247A (en) Substituted or unsubstituted p-alkanoyl toluenes as anti-diabetic agents
US4195089A (en) Synergistic composition for malaria
US3873708A (en) N-sulfamoyl-substituted-piperidines as anti-tussive agents
US4556664A (en) Method and composition for the treatment of cardiac arrhythmias
GB2195532A (en) Therapeutic agent for treatment of disorders associated with cerebral ischemia
US3642993A (en) Pharmaceutical composition containing 2-methyl - 5 - phenyl - 1 2-dihydro-3h-2-benzazepine for treatment of a condition associated with anxiety or tension